Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

New “Placental Tissue Amendment” Bill Clarifies Disclosures Required to Perform Stem Cell Therapies in Utah

March 11, 2024 By Cade Hildreth, Founder & President Leave a Comment

The “Placental Tissue Amendment Bill”, Part of SB 0199, Has Been Passed by the Utah State Legislature.

The “Placental Tissue Amendment Bill“, part of SB 0199, recently passed by the Utah State Legislature, introduces specific requirements for healthcare providers administering treatments involving placental stem cells. The key focus of this bill is to ensure that patients receive adequate disclosures regarding the nature of the treatment, particularly if it involves stem cell therapy that hasn’t been approved by the United States Food and Drug Administration (FDA). [Read more…]

Novo Holdings to Acquire the CDMO Catalent for a Staggering $16.5 Billion Enterprise Value

March 11, 2024 By Cade Hildreth, Founder & President Leave a Comment

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024

COPENHAGEN, Denmark and SOMERSET, N.J. – February 5, 2024– Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, announced that they entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. [Read more…]

2024 HEALinc Future Health Summit to Convene Experts in Longevity and Regenerative Health

March 10, 2024 By Cade Hildreth, Founder & President Leave a Comment

Over April 28-30th, 2024, on Paradise Island in The Bahamas, the 2024 HEALinc Future Health Summit will be convening experts from across the fields of longevity, cellular medicine, and regenerative health. The event will bring together the world’s top scientists, investors, healthcare providers, longevity tech companies, and stem cell companies. By attending, you will be positioned to learn about cutting-edge future health medicines and technologies that can support peak performance at any age. [Read more…]

First Patient Treated in Phase 2 GvHD Trial

March 5, 2024 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 5 March 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). [Read more…]

Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development.

WILMINGTON, Mass., February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics. [Read more…]